Breakdown of the blood-eye barrier in choroidal melanoma after proton beam radiotherapy.


Journal

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 04 04 2019
accepted: 02 07 2019
revised: 25 06 2019
pubmed: 14 7 2019
medline: 23 1 2020
entrez: 14 7 2019
Statut: ppublish

Résumé

Irradiation of choroidal melanoma is a safe and globe preserving procedure. Chronic inflammatory processes and ischemia are the main reasons for secondary enucleation in the long run. The aim of this study was to determine whether intraocular inflammation and especially inflammatory response after proton beam therapy (PBT) is related to primary tumor characteristics such as height, tumor volume, and initial flare values. Twenty-six patients treated for uveal melanoma using PBT were included. All patients were examined for signs of inflammation using laser flare photometry (LFP). Each examination included assessment of the melanoma and fellow eye (which acted as the control) and imaging of the melanoma. Significant differences of flare values between melanoma eyes and control group were found both at baseline (median 17.65 ph/ms (min 4, max 37.10), 7.45 ph/ms (min 0.80, max 16.40), respectively) and during follow-up (median 21.45 ph/ms (min 4.5, max 70.90); 6.05 ph/ms (min 2.40, max 16.40), respectively) (p < 0.001, Wilcoxon test). Flare values in melanoma eyes increased significantly after PBT (p = 0.005, Wilcoxon test) and after a follow-up of 94 days (median, 7-420 days). Flare values of the control group did not change (p = 0.946, Wilcoxon test). The increase of flare values correlated significantly with maximum tumor height and volume (Spearman-Rho 0.633, p = 0.001 and 0.519, p = 0.007, respectively). LFP has proven to show significantly higher flare values in melanoma eyes as compared with the control group and provides data on the course of the inflammatory response after treatment. It may ease treatment planning both at baseline and during follow-up.

Identifiants

pubmed: 31300898
doi: 10.1007/s00417-019-04413-z
pii: 10.1007/s00417-019-04413-z
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2323-2328

Références

Arch Ophthalmol. 1979 Jul;97(7):1311-4
pubmed: 313204
Ophthalmologica. 1999;213(3):194-6
pubmed: 10202294
Eur J Ophthalmol. 2013 May-Jun;23(3):399-409
pubmed: 23483500
Am J Ophthalmol. 2015 Oct;160(4):628-36
pubmed: 26133249
Br J Ophthalmol. 2014 Jun;98(6):775-9
pubmed: 24568869
Arch Ophthalmol. 2006 Dec;124(12):1684-93
pubmed: 17159027
Am J Ophthalmol. 2017 Jun;178:94-100
pubmed: 28365241
Phys Med Biol. 2001 Mar;46(3):671-86
pubmed: 11277216
Eye (Lond). 2013 Feb;27(2):163-71
pubmed: 23196647
Ocul Oncol Pathol. 2014 Oct;1(1):24-33
pubmed: 27175359
Br J Ophthalmol. 2001 Nov;85(11):1305-8
pubmed: 11673294
Eur J Ophthalmol. 2011 Nov-Dec;21(6):796-801
pubmed: 21445839
Jpn J Ophthalmol. 2017 Jan;61(1):21-42
pubmed: 27888376
Phys Med Biol. 2002 Feb 21;47(4):593-613
pubmed: 11900193
Am J Ophthalmol. 2003 Jul;136(1):180-2
pubmed: 12834689
Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2085-93
pubmed: 11481276
Arch Ophthalmol. 2006 Oct;124(10):1428-34
pubmed: 17030710
Invest Ophthalmol Vis Sci. 2012 Oct 01;53(11):6748-55
pubmed: 22930720
Eur J Ophthalmol. 2017 Aug 30;27(5):596-600
pubmed: 28218368
Ophthalmology. 2015 May;122(5):1023-9
pubmed: 25687025
Ophthalmology. 2010 May;117(5):1013-23
pubmed: 20097428
Am J Ophthalmol. 1994 Apr 15;117(4):521-8
pubmed: 8154537
Br J Ophthalmol. 1995 Apr;79(4):354-7
pubmed: 7742283
Graefes Arch Clin Exp Ophthalmol. 2016 Jul;254(7):1379-85
pubmed: 26960442

Auteurs

Annette Hager (A)

Augenklinik, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.

Friederike Meissner (F)

Augenklinik, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.

Aline-Isabel Riechardt (AI)

Augenklinik, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.

Theresa Bonaventura (T)

Augenklinik, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.

Julia Löwen (J)

Augenklinik, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.

Jens Heufelder (J)

Augenklinik, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany. Jens.heufelder@charite.de.
BerlinProtonen am Helmholtz-Zentrum Berlin für Materialien und Energie, Charité - Universitätsmedizin Berlin, Berlin, Germany. Jens.heufelder@charite.de.

Antonia M Joussen (AM)

Augenklinik, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH